Abstract
Hypogonadism syndrome, characterized by testosterone deficiency, negatively affects the physical, metabolic and psychoemotional health of men. The main treatments for hypogonadism include androgen replacement and androgen stimulating therapy. Androgen replacement therapy, represented by transdermal and injectable forms of testosterone, effectively restores testosterone levels, improves sexual function, muscle mass, bone mineral density and metabolic parameters. However, it suppresses spermatogenesis, which limits its use in men planning fatherhood. Androgen stimulating therapy, including gonadotropins, antiestrogens and aromatase inhibitors, stimulates the production of endogenous testosterone and spermatogenesis. Gonadotropins demonstrate high efficacy, but their long-term use is complicated by the need for frequent injections and the lack of long-term results. The long-term studies presented in the review confirm the safety and effectiveness of androgen replacement therapy, but data on androgen stimulating therapy are limited in follow-up time to a maximum of two years.